Valuation: StemRIM

Market Cap 18.68B 119M 106M 98.21M 89.04M 167M 11.3B 169M 1.17B 467M 5.92B 447M 437M P/E 2024
-13.6x
P/E 2025 -10.2x
Enterprise Value 11.68B 74.46M 66.49M 61.44M 55.7M 104M 7.07B 106M 734M 292M 3.71B 280M 274M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
52.06%
Yield 2024 *
-
Yield 2025 -
Oct. 07 StemRIM Inc. Announces Patent Registration for Stem Cell Gene Therapy Technology SR-GT1 Aimed at Curative Treatment of Dystrophic Epidermolysis Bullosa in USA CI
Sep. 25 StemRIM Inc. Announces Patent Registration In South Korea For Use Of Redasemtide As Additional Therapeutic Indication Of Cartilage Disorders CI
Sep. 09 StemRIM Reports Earnings Results for the Full Year Ended July 31, 2026 CI
Jul. 22 Stemrim Announces Patent Registration in Mexico for Redasemtide as Therapeutic Agent for Cartilage Disorders CI
Jul. 08 StemRIM Inc. Announces Patent Registration For Stem Cell Gene Therapy Technology SR-GT1 Aimed At Curative Treatment Of Dystrophic Epidermolysis Bullosa In South Korea CI
Jun. 17 StemRIM Announces Patent Registration for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders CI
Jun. 16 StemRIM Inc Announces Patent Registration In Russia For Redasemtide As Therapeutic Drug For Fatty Liver And Non-Alcoholic Steatohepatitis CI
Jun. 16 StemRIM to Register Russian Patent of Drug Candidate for Fatty Liver Disease MT
Jun. 10 StemRIM Reports Earnings Results for the Nine Months Ended April 30, 2026 CI
May. 12 Stemrim Inc. Announces Progress for Regeneration-Inducing Medicine Redasemtide CI
Apr. 15 StemRIM Finishes Enrollment in Phase 1/2 Redasemtide Study MT
Apr. 15 StemRIM Inc. Announces Completion of Patient Enrollment in Phase 1/2 InvestigatorInitiated Clinical Trial of Redasemtide for Patients with Ischemic Cardiomyopathy CI
Mar. 11 StemRIM Reports Earnings Results for the Half Year Ended January 31, 2026 CI
1 day+2.07%
1 week-9.76%
Current month-12.94%
1 month-16.38%
3 months-50.67%
6 months-52.10%
Current year-43.73%
1 week 141
Extreme 141
163
1 month 141
Extreme 141
185
Current year 141
Extreme 141
368
1 year 141
Extreme 141
368
3 years 141
Extreme 141
735
5 years 141
Extreme 141
1,518
10 years 141
Extreme 141
1,518
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 2022-09-30
Chief Executive Officer 58 2023-10-24
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 66 2007-01-31
Director/Board Member 58 2019-02-28
Director/Board Member 54 2019-09-30
Change 5-day change 1-year change 3-year change Capi.($)
+2.07%-9.76%-49.49%-76.77% 59.16M
-2.54%+1.31%+55.10%+120.84% 1,135B
-1.42%+3.23%+37.07%+74.26% 636B
+0.16%+0.08%+25.14%+97.36% 505B
-0.31%+3.09%+43.92%+64.55% 378B
-1.34%-0.47%+66.63%+40.56% 358B
-0.68%+2.65%+22.46%+51.48% 295B
-1.20%+3.04%+2.62%+26.97% 266B
-1.79%+1.57%+49.97%+60.87% 237B
-0.73%-0.10%+29.24%+101.19% 193B
Average -0.78%+0.98%+28.27%+56.13% 400.44B
Weighted average by Cap. -1.35%+2.66%+40.99%+82.13%

Financials

2024 2025
Net sales - -
Net income -2.02B -12.88M -11.51M -10.63M -9.64M -18.04M -1.22B -18.32M -127M -50.53M -641M -48.38M -47.36M -1.93B -12.29M -10.98M -10.14M -9.2M -17.21M -1.17B -17.48M -121M -48.21M -612M -46.16M -45.18M
Net Debt -8.41B -53.59M -47.85M -44.22M -40.09M -75.04M -5.09B -76.21M -528M -210M -2.67B -201M -197M -6.99B -44.57M -39.8M -36.77M -33.34M -62.41M -4.23B -63.38M -439M -175M -2.22B -167M -164M
Projected Income Statement - Annual - StemRIM
Logo StemRIM
StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Employees
-
Date Price Change Volume
26-10-23 ¥148.00 +2.07% 499,800
26-10-22 ¥145.00 -3.33% 574,900
26-10-21 ¥150.00 -2.60% 744,400
26-10-20 ¥154.00 -3.14% 790,700
26-10-19 ¥159.00 -3.05% 222,500
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - StemRIM

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - StemRIM
  1. Stock Market
  2. Stocks
  3. 4599 Stock